NIH-Funding

Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) (U54)

NIH Funding Announcements - Wed, 11/15/2017 - 05:22
Funding Opportunity PAR-18-361 from the NIH Guide for Grants and Contracts. This funding opportunity seeks to support the Comprehensive Partnerships to Advance Cancer Health Equity (CPACHE) Program. The CPACHE Program develops and maintains comprehensive, long-term, and mutually beneficial partnerships between institutions serving underserved health disparity population and underrepresented students (ISUPSs) and NCI-designated Cancer Centers (CCs). The program aims to achieve a stronger national cancer program and address challenges in cancer and cancer disparities research, education and outreach, as well as their impact on underserved populations. The institutions in each partnership are expected to work collaboratively to: 1) increase the cancer research and cancer research education capacity of the ISUPSs; 2) increase the number of students and investigators from underrepresented populations engaged in cancer research; 3) improve the effectiveness of CCs in developing and sustaining research programs focused on cancer health disparities and increase the number of investigators and students conducting cancer health disparities research; and 4) develop and implement cancer-related activities that benefit the surrounding underserved communities.
Categories: NIH-Funding

NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22-Clinical Trial Required)

NIH Funding Announcements - Wed, 11/15/2017 - 04:36
Funding Opportunity PAR-18-360 from the NIH Guide for Grants and Contracts. The purpose of the NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22) program is to provide highly qualified dentists in NIH Intramural postdoctoral fellowship positions with an opportunity to receive further mentored research experience in the NIH Intramural program, and then to provide them with independent funding to facilitate the transition of their research programs as new investigators at extramural institutions. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-16-140).
Categories: NIH-Funding

Notice of Change in Participant Eligibility for PAR-17-051 "Postbaccalaureate Research Education Program (PREP) (R25)"

NIH Funding Announcements - Wed, 11/15/2017 - 03:24
Notice NOT-GM-18-007 from the NIH Guide for Grants and Contracts
Categories: NIH-Funding

NIDCR Mentored Career Development Award to Promote Diversity in the Dental, Oral and Craniofacial Research Workforce (K01-Clinical Trial Required)

NIH Funding Announcements - Wed, 11/15/2017 - 03:22
Funding Opportunity PAR-18-359 from the NIH Guide for Grants and Contracts. The purpose of this NIDCR Mentored Career Development Award is to enhance the diversity of the independently funded dental, oral and craniofacial research workforce by providing a mentored research experience for eligible postdoctoral fellows and junior faculty who are from groups that have been shown to be nationally underrepresented in the basic and clinical biomedical, behavioral, and social sciences. This award provides salary and research support for a sustained period of protected time for intensive research career development under the guidance of an experienced mentor. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (PAR-16-321).
Categories: NIH-Funding

By: Bioinorganic Chemist

WriteEdit-Grant Questions Blog - Tue, 11/14/2017 - 18:09

R15 in reversal, I had a ~20% R01 at NIGMS that was submitted in June 2016 that was being considered for funding until the very end; 2 JIT requests and lots of updates and convos with the PO, and a rebuttal request. It didn’t end up getting funded and we re-submitted a A1 in June 2017 that did not even get discussed.

My take home is what has been echoed by others- its frustrating, but keep submitting. If put in 10 *PERFECT* grants, you should only expect 1 (maybe 2) to get funded. It’s the life we chose!

Categories: NIH-Funding

By: R15 In Reverse!

WriteEdit-Grant Questions Blog - Tue, 11/14/2017 - 17:36

Update: This has been brutal and just completely unacceptable. Current feedback is “oh sorry the SRO made a mistake”. Now I’m sitting here with no grant submitted for review this cycle/fiscal year. I may have to go higher up the chain. I don’t even care about not getting the summary statement and critiques (although I will keep asking for them at this point). I followed the instructions given by the SRO and they threw him under the bus and offered no compromise.

Categories: NIH-Funding

The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)

NIH Funding Announcements - Tue, 11/14/2017 - 12:03
Funding Opportunity RFA-CA-18-001 from the NIH Guide for Grants and Contracts. The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.
Categories: NIH-Funding

Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01- Clinical Trial Required)

NIH Funding Announcements - Tue, 11/14/2017 - 11:49
Funding Opportunity RFA-MH-18-707 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support confirmatory efficacy testing of non-pharmacological therapeutic and preventive interventions for mental disorders in adults and children through an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development, effectiveness testing, or dissemination of the intervention. Interventions to be studied include, but are not limited to behavioral, cognitive, interpersonal, and device-based (both invasive/surgically implanted as well as noninvasive/transcranial) approaches, or a combination thereof. Interventions appropriate for efficacy testing must be based on a compelling scientific rationale, previous demonstration that the intervention engages and alters the hypothesized mechanism of action, a preliminary efficacy signal, and must address an unmet therapeutic need. Support will be provided for a trial of the intervention's efficacy that includes measurement of the hypothesized mechanism of action and the relationship between change in the mechanism and change in functional or clinical effects. Ultimately, this FOA is intended to support a sufficiently-powered efficacy trial to determine the intervention's potential for significant clinical benefit.
Categories: NIH-Funding

Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required)

NIH Funding Announcements - Tue, 11/14/2017 - 11:49
Funding Opportunity RFA-MH-18-706 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot research consistent with NIMH's priorities for: 1) effectiveness research on preventive and therapeutic interventions with previously demonstrated efficacy, for use with broader target populations or for use in community practice settings, and 2) research on the development and preliminary testing of innovative services interventions. Applications should provide resources for evaluating the feasibility, tolerability, acceptability and safety of approaches to improve mental health/functional outcomes, to modify risk factors, or to improve service delivery, and for obtaining the preliminary data needed as a pre-requisite to a larger-scale intervention trial (e.g., comparative effectiveness study, practical trial) or large-scale services study.
Categories: NIH-Funding

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33- Clinical Trial Required)

NIH Funding Announcements - Tue, 11/14/2017 - 11:48
Funding Opportunity RFA-MH-18-705 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy are novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to 3 years for studies to replicate previous target engagement findings, and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk.
Categories: NIH-Funding

Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required)

NIH Funding Announcements - Tue, 11/14/2017 - 11:48
Funding Opportunity RFA-MH-18-704 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the efficient pilot testing of novel psychosocial therapeutic and preventive interventions for mental disorders in adults and children, using an experimental therapeutics approach. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support "go/no-go" decisions about further development or testing of the intervention. This FOA supports the development and testing of innovative psychosocial intervention approaches where the target and/or the intervention strategy is novel. Targets might include, but are not limited to, potentially modifiable behavioral, cognitive, affective and/or interpersonal factors or processes, neural circuits or neural activity subserving specific behaviors or cognitive processes, and/or other neurobiological mechanisms associated with risk for, causation of, or maintenance of a mental disorder. Eligible psychosocial intervention strategies might include in-person or technology-assisted delivery, provided the target and/or the intervention strategy is novel. This FOA supports the development and testing of novel psychosocial interventions, as defined above, as monotherapies or as augmentations to standard treatment. Support will be provided for up to two years (R61 phase) for preliminary milestone-driven testing of the intervention's impact on a target (a process or mechanism associated with risk for, causation, or maintenance of a clinical condition), that is, its target engagement. Contingent on meeting "go/no-go" milestones in the R61 phase, up to 3 years of additional support (R33 phase) may be provided for studies to replicate target engagement and relate change in the intervention target/mechanism to clinical benefit. Ultimately, this R61/R33 FOA is intended to speed the translation of emerging basic science findings of mechanisms and processes underlying mental disorders into novel interventions that can be efficiently tested for their promise in restoring function and reducing symptoms for those living with mental disorders, or for preventing mental disorders among those at risk.
Categories: NIH-Funding

Early Stage Testing of Pharmacologic or Device -based Interventions for the Treatment of Mental Health Disorders (R33- Clinical Trial Required)

NIH Funding Announcements - Tue, 11/14/2017 - 11:48
Funding Opportunity RFA-MH-18-703 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect. Pediatric, adult and geriatric focused interventions are appropriate for this FOA. This R33 FOA supports single phased clinical trial awards. Applicants proposing high risk projects are encouraged to apply to the companion FOA, RFA-MH-18-702.
Categories: NIH-Funding

Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33-Clinical Trial Required)

NIH Funding Announcements - Tue, 11/14/2017 - 11:48
Funding Opportunity RFA-MH-18-702 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support the early stage testing of pharmacologic interventions with novel mechanisms of action, or device-based interventions, for the treatment of symptoms or domains of altered functions in individuals with mental illness (e.g., schizophrenia, depression, autism, obsessive compulsive disorder, anxiety, bipolar disorder). Early intervention studies are also encouraged where symptoms of a disorder have been identified in subjects (a prodromal phase), prior to full diagnostic criteria being met. Ultimately, this FOA is intended to support early stage testing of pharmacologic or device-based interventions using a protocol design where the presumed mechanism of action of the intervention is adequately tested, to provide meaningful information where target modulation yields a dose-dependent neurophysiological/clinical/behavioral effect.
Categories: NIH-Funding

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01- Clinical Trial Required)

NIH Funding Announcements - Tue, 11/14/2017 - 11:48
Funding Opportunity RFA-MH-18-701 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions.
Categories: NIH-Funding

Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01-Clinical Trial Required)

NIH Funding Announcements - Tue, 11/14/2017 - 11:48
Funding Opportunity RFA-MH-18-700 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks to support clinical trials to establish the effectiveness of interventions and to test hypotheses regarding moderators, mediators, and mechanisms of action of these interventions. This FOA supports clinical trials designed to test the therapeutic value of treatment and preventive interventions for which there is already evidence of efficacy, for use in community and practice settings. Applications might include research to evaluate the effectiveness or increase the clinical impact of pharmacologic, somatic, psychosocial (psychotherapeutic, behavioral), device-based, rehabilitative and combination interventions to prevent or treat mental illness. This FOA also supports clinical trials to test patient-, provider-, organizational-, or systems-level services interventions to improve access, continuity, quality, equity, and/or value of services. The intervention research covered under this announcement is explicitly focused on practice-relevant questions.
Categories: NIH-Funding

By: writedit

WriteEdit-Grant Questions Blog - Tue, 11/14/2017 - 00:22

It sounds like you should be okay with the A1, especially if you can provide your PO with a response to not the dissenting reviewer’s critique in detail but whatever was highlighted in the summary of discussion (you could even send a 1-page response draft in advance of talking with him/her). The fact that you have been talking with your PO all along is great, as is the significant improvement in score – all of which NCI will take into account (plus your ESI status). Even if NCI does not reach the 25th percentile for NGRI, which is doubtful (but not impossible, depending on their FY18 appropriation), they will make exceptions for select pay, and your PO should be able to make a good case for you. Just be prepared with a response and any science updates when you next communicate with your PO.

Categories: NIH-Funding

By: Zhuoli Zhang

WriteEdit-Grant Questions Blog - Mon, 11/13/2017 - 16:51

thank you very much

Categories: NIH-Funding

By: Andrew

WriteEdit-Grant Questions Blog - Mon, 11/13/2017 - 16:30

My R01- A1 was recently reviewed and was awarded a percentile in the low 20’s (NCI is the IC). I am an ESI. There was difference in opinion during the discussion with 2 reviewers giving high-impact scores for significance/ innovation/ approach and one reviewer dissenting. Strong significance/ innovation was also recorded in the A0 and the resubmission improved the score by greater than 10 percentile points. I think my PO likes the project based on our post- A0 discussion but I have not spoken to them yet. I would be grateful for your feedback on what my options are. The dissenting reviewer’s critique did not expose a fatal flaw or anything- it seemed more due to myopic vision than anything else. As such, I am not sure it can be improved by resubmission (virtual A2) as it was of philosophical nature. I am within the NGRI bracket but then again, this is NCI. Would be grateful for your thoughts.

Categories: NIH-Funding